Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Japan OKs 56 Trillion Yen Stimulus Package, Spells Out Support for Japan-Made Drugs and Vaccines
November 22, 2021
- Amitiza Gets Label Update for Opioid-Induced Constipation
November 22, 2021
- Japan to Go Ahead with Procedures for Pediatric Vaccination without Preconceptions: Minister
November 22, 2021
- Japan Sets Up Vaccine Team Confab of Sr. Vice Ministers
November 22, 2021
- Amgen’s KRAS Inhibitor, MSD’s Cough Drug Up for PAFSC Review on Dec. 2
November 19, 2021
- Japan Panel Discusses Safety, Immunity Rules for Envisaged Emergency Approval Scheme
November 19, 2021
- Japan Looks to Start Pediatric COVID-19 Vaccinations from February
November 19, 2021
- Ex-Minister Tamura Says Efficacy/Safety Confirmation Important in Emergency Approval, Wary on Macroeconomic Indexing
November 18, 2021
- Chuikyo Calls for Smooth Transition to Fertility Treatment Coverage from Current Subsidy System
November 18, 2021
- Vynmac Listing OK’ed, but Chuikyo Urges Response to Market Expansion with Similar Upgrade
November 18, 2021
- Health Minister Stresses Basic 8-Month Interval for Booster Shot
November 17, 2021
- November Listing OK’ed for Cibinqo, Retevmo, Padcev and More
November 17, 2021
- MHLW Panel to Discuss Idorsia’s Cerebral Vasospasm Drug on Nov. 26; Efient Up for Review Again
November 17, 2021
- Sclerosing Cholangitis Added to ADR List in Tecentriq Label
November 17, 2021
- MSD’s Noxafil Price to Be Trimmed 0.5% under CEA Scheme
November 17, 2021
- Takeda’s Cell Therapy Alofisel Gets 5.62 Million Yen Price Tag
November 17, 2021
- 50 Billion Yen-Plus Peak Sales Projected for Pfizer’s Vynmac, Listing Set for Nov. 25
November 17, 2021
- Japan Panel Agrees to Give Free “Catch-Up” HPV Shots
November 16, 2021
- Chuikyo Subcommittee OKs Basic SaMD Reimbursement Rule
November 16, 2021
- PMDA’s SaMD Consultation Desk Handling 30 Inquiries per Month
November 16, 2021
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…